General
Preferred name
PEFICITINIB
Synonyms
ASP-015K ()
P&D ID
PD047695
CAS
944118-01-8
Tags
available
drug
Approved by
PMDA
First approval
2019
Drug indication
Psoriasis vulgaris
Rheumatoid arthritis
Drug Status
approved
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Peficitinib is an oral Janus kinase inhibitor that was developed for potential anti-inflammatory action in autoimmune diseases including rheumatoid arthritis , psoriasis and ulcerative colitis . (GtoPdb)
Compound Sets
4
DrugCentral
5481
DrugCentral Approved Drugs
5481
DrugMAP
DMZ1UOI
Guide to Pharmacology
8315
External IDs
8
Properties
(calculated by RDKit )
Molecular Weight
326.17
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
4
Rotatable Bonds
3
Ring Count
6
Aromatic Ring Count
2
cLogP
2.01
TPSA
104.03
Fraction CSP3
0.56
Chiral centers
5.0
Largest ring
6.0
QED
0.69
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Source data